ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

7 links6 made here, not in the record7 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06840782First-lineImmunotherapy-basedStandard of Care and LocalAblative Treatments forOligometastatic Non-smallCell Lung Cancer Patients.Gustave Roussy, Cancer Campus,Phase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Version of 2026-11-05CONDITIONSCarcinoma, Non-Small-Cell L…No longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundBackgroundNivolumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · BackgroundBackgroundIpilimumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · BackgroundBackgroundDurvalumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · BackgroundBackgroundTremelimumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · BackgroundBackgroundAtezolizumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · establishedBackground · established

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here1 judgment on this link
NCT06840782gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 1, 2026, 8:22 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 2Nivolumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 2Ipilimumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Durvalumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Tremelimumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Atezolizumabmade hereClaude Opus 5.5Background · establishedCurrent
Nov 5The record itselfClinicalTrials.gov recordVersion of 2026-11-05Record change
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.